Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122
This study is recruiting at 5 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of [225Ac]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Full-Life Technologies UK Limited
- Last updated on ClinicalTrials.gov
- May 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- City of Hope Medical Center · Duarte, CA
- Chao Family Comprehensive Cancer Center · Irvine, CA
- University of Stanford · Stanford, CA
Ohio · 1
- University Hospital of Cleveland · Cleveland, OH
Virginia · 1
- University of Virginia Cancer Center · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.